aTyr Pharma, Inc. announced that the last patient has completed their last visit in the company’s Phase 3 EFZO-FIT™ study of efzofitimod. This pivotal study is evaluating efzofitimod in patients with pulmonary sarcoidosis, a major form of interstitial lung disease.
The completion of this global Phase 3 study, which is the largest interventional study conducted for sarcoidosis patients to date, is a major accomplishment for aTyr and the sarcoidosis community. Topline results from this study are expected in the third quarter of 2025.
The EFZO-FIT™ study is a 52-week randomized, double-blind, placebo-controlled trial that enrolled 268 subjects across multiple centers. It aims to evaluate efzofitimod's potential to reduce steroid burden and improve quality of life for patients with chronic pulmonary sarcoidosis.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.